Related Experiment Video
Updated: Jul 1, 2026

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster
Published on: October 20, 2023
Sleep dysfunction in heart failure
1Shahrokh Javaheri, MD Sleepcare Diagnostics, 4780 Socialville-Fosters Road, Cincinnati, OH 45040, USA. Javaheri@snorenomore.com.
Insights
Sleep disorders like sleep apnea are common in heart failure patients and linked to higher mortality. Effective CPAP treatment improves survival, with alternative therapies available for non-responders.
Area of Science:
- Cardiology
- Sleep Medicine
- Pulmonology
Background:
- Chronic congestive heart failure (CHF) is a widespread, progressive condition with significant morbidity, mortality, and economic burden.
- Sleep disorders are highly prevalent in CHF patients, affecting both systolic and diastolic dysfunction, particularly in older individuals.
- Existing research primarily focuses on systolic heart failure, with less systematic study on diastolic dysfunction and its associated sleep issues.
Purpose of the Study:
- To review the types and impact of sleep disorders in patients with chronic congestive heart failure.
- To evaluate current and alternative treatment strategies for various sleep disorders in heart failure.
- To highlight the association between sleep disorders, treatment efficacy, and patient survival in heart failure.
Main Methods:
- Systematic review of prospective studies on sleep disorders in heart failure patients.
- Analysis of treatment outcomes for obstructive sleep apnea (OSA) and central sleep apnea (CSA) using positive airway pressure (PAP) devices.
- Evaluation of therapeutic options for periodic limb movements (PLM) and insomnia in the context of heart failure.
Main Results:
- Obstructive sleep apnea and central sleep apnea are common in CHF and linked to increased mortality.
- Continuous positive airway pressure (CPAP) improves survival in CHF patients with both OSA and CSA.
- Alternative therapies like pressure support servo-ventilators and nocturnal oxygen are effective for CPAP-refractory CSA; pramipexole/ropinirole for RLS/PLM; ramelteon for insomnia.
Conclusions:
- Sleep disorders significantly impact CHF prognosis and require effective management.
- CPAP therapy is a cornerstone treatment for sleep apnea in heart failure, improving survival.
- A multi-faceted approach addressing various sleep disturbances is crucial for optimizing outcomes in patients with chronic congestive heart failure.
Abstract:
Chronic congestive heart failure is a highly prevalent and progressive disorder associated with excess morbidity and mortality; it has huge economic impact. Left heart failure may be systolic or may occur as isolated diastolic dysfunction. The diastolic form predominates in older people. Sleep disorders are frequent in both types. Most systematic studies have been performed in patients with systolic heart failure. Prospective studies show the presence of obstructive and central sleep apnea, periodic limb movements, and significant alterations in sleep architecture, characterized by poor efficiency, excess stage 1 and arousals, and lack of deep sleep. Both obstructive sleep apnea and central sleep apnea occur in patients with heart failure and have been shown to be associated with excess mortality. Obstructive sleep apnea is best treated with continuous positive airway pressure (CPAP) devices. Central sleep apnea is also best treated with CPAP, but only about 50% of the patients are considered responders. Survival improves when heart failure patients are effectively treated with CPAP for both central and obstructive sleep apnea. A new positive airway pressure device, a pressure support servo-ventilator, is the next best choice for heart failure patients whose central sleep apnea does not respond to CPAP. Nocturnal oxygen should be used for patients whose central sleep apnea does not respond to positive pressure devices. Both periodic limb movements and insomnia could have adverse hemodynamic consequences for the failing heart. There are no guidelines or long-term studies regarding treatment of these conditions in heart failure. For restless legs syndrome with or without periodic limb movements, pramipexole and ropinirole have been approved. Treatment of insomnia comorbid with heart failure depends on the cause. In the absence of any known cause, a trial of ramelteon is the first choice.
Related Concept Videos
Heart Failure VII: Nursing Interventions
Heart Failure VI: Adjunct Therapies
Heart Failure III: Clinical Manifestations
Pathophysiology of Heart Failure
Heart Failure I: Introduction
Heart Failure Drugs: β-Blockers
